Madrigal Pharmaceuticals has been granted three new U.S. patents for its drug Resmetirom, extending intellectual property protection for key formulations and treatment methods. These patents, covering F2/F3 MASH and F4c cirrhosis, are expected to bolster the company's market position and revenue longevity for its flagship product.
Madrigal Pharmaceuticals announced the issuance of three new U.S. patents for Resmetirom (Rezdiffra), its recently approved drug for MASH. These patents extend protection for specific dosing regimens in F2/F3 MASH patients, co-administration with rosuvastatin, and treatment of well-compensated cirrhosis (F4c) until 2042 and 2045. This is a significant positive development for Madrigal as it strengthens the intellectual property moat around its primary revenue driver, reducing the threat of generic competition for a longer period. For traders, this implies increased revenue predictability and long-term value for MDGL, potentially leading to a positive re-evaluation of the stock. The short-term impact could be a modest bump in share price, while the long-term implication is enhanced market exclusivity and profitability.